News & Analysis on Clinical Trial Services & Contract Research And Development
AAPS PharmSci 360
The predictive value of animal models is less than 50%, which makes them less informative than a coin flip, says AAPS speaker – who also argues that clinical trial participants are not fully aware of the risks.
AAPS PharmSci 360
More than six million pet dogs are diagnosed with cancer every year – posing researchers with the opportunity to co-develop drugs for humans and animals.
The FDA has proposed a study to create a non-animal based model for drug development as part of its overall commitment to reduce the number of animals used in research.
Strong collaboration across the company’s clinical, commercial, and integration solutions teams led to a “solid performance,” said Syneos CEO Alistair MacDonald.
Synteract’s clients will benefit from a single source model, says CEO, following the acquisition of KinderPharm, a PA-based CRO focused on all phases of pediatric drug development.
PHARMA INTEGRATES
Without a win-win contract in place, innovators will be driven to manufacture in-house, says JM executive.
A licensing agreement with MPP will allow access to Mavyret in a number of low- and middle-income countries and territories at ‘affordable prices’.
Messenger RNA is demonstrating success in vaccine manufacturing and CureVac is giving it the place to do so with the development of a prophylactic vaccine with mRNA at its core.